AFAP1 and prostate cancer: It might be due to these tumor-promoting actions that lncRNA AFAP1-AS1 powerfully heightened cisplatin-resistance of esophageal squamous cell carcinoma [52]/laryngeal carcinoma cells [53], paclitaxel-resistance of prostate cancer cells [54], 5-Fu-/cisplatin-resistance of non-small cell lung cancer cells [55], as well as 5-Fu/adriamycin/paclitaxel/cisplatin-resistance of TNBC cells manifested in this study (Figure 1C–1F).